Abstract: A purification apparatus comprising a filtration unit comprising filtration screens, a disinfection unit comprising a source of disinfecting light and a passage for filtrate from the filtration unit to the disinfection unit. The filtration unit may be selected from at least one static drum, at least one rotating drum, and at least one filter pack. Louver vanes or baffles may be used in the passage to create turbulence and direct flow. A process for removing particulate matter and disinfecting a process flow comprises the steps of filtering the process flow to remove particulate matter, directing the filtrate to a source of disinfection light while creating turbulence in the filtrate and disinfecting the filtrate.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (PANEC-1 and PANEC-2) from human pancreas cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode PANEC-1 and PANEC-2, expression vectors for the production of purified PANEC-1 and PANEC-2, antibodies capable of binding specifically to PANEC-1 and PANEC-2, hybridization probes or oligonucleotides for the detection of PANEC-1- or PANEC-2-encoding nucleotide sequences, genetically engineered host cells for the expression of PANEC-1 and PANEC-2, diagnostic tests for chemokine activation based on PANEC-1- and PANEC-2-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.

Abstract: Systems and methods are disclosed that relate to providing information about an item available for sale. This item is selected for purchase by a buyer, and the location information of the buyer and seller are exchanged. As the buyer approaches the seller, the location of the seller is reported to the buyer. The sale can be completed upon the arrival of the buyer to the seller.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (PANEC-1 and PANEC-2) from human pancreas cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode PANEC-1 and PANEC-2, expression vectors for the production of purified PANEC-1 and PANEC-2, antibodies capable of binding specifically to PANEC-1 and PANEC-2, hybridization probes or oligonucleotides for the detection of PANEC-1- or PANEC-2-encoding nucleotide sequences, genetically engineered host cells for the expression of PANEC-1 and PANEC-2, diagnostic tests for chemokine activation based on PANEC-1- and PANEC-2-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (PANEC-1 and PANEC-2) from human pancreas cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode PANEC-1 and PANEC-2, expression vectors for the production of purified PANEC-1 and PANEC-2, antibodies capable of binding specifically to PANEC-1 and PANEC-2, hybridization probes or oligonucleotides for the detection of PANEC-1- or PANEC-2- encoding nucleotide sequences, genetically engineered host cells for the expression of PANEC-1 and PANEC-2, diagnostic tests for chemokine activation based on PANEC-1- and PANEC-2 -encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new cathepsin C homolog (RCP) expressed in THP-1 cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode RCP, expression vectors for the production of purified RCP, antibodies capable of binding specifically to RCP, hybridization probes or oligonucleotides for the detection of RCP-encoding nucleotide sequences, genetically engineered host cells for the expression of RCP, diagnostic tests for activation of monocyte/macrophages based on RCP-encoding nucleic acid molecules, and use of the protein to produce antibodies capable of binding specifically to the protein and use of the protein to screen for inhibitors.

Abstract: The present invention provides a polynucleotide (hjak2) which identifies and encodes a novel human Jak2 kinase (HJAK2) which was expressed in the placenta. The present invention also provides for antisense molecules and oligomers designed from the nucleotide sequence or its antisense. The invention further provides genetically engineered expression vectors and host cells for the production of purified HJAK2 peptide, antibodies capable of binding to HJAK2, inhibitors which bind to HJAK2 and pharmaceutical compositions based on HJAK2 specific antibodies or inhibitors. The invention specifically provides for diagnostic assays based on altered hjak2 expression and which allow identification of such a condition. These assays utilize probes which comprise oligomers, fragments, or portions of hjak2 or its regulatory elements or antibodies specifically binding HJAK2.

Abstract: The present invention provides a polynucleotide (hjak2) which identifies and encodes a novel human Jak2 kinase (HJAK2) which was expressed in the placenta. The present invention also provides for antisense molecules and oligomers designed from the nucleotide sequence or its antisense. The invention further provides genetically engineered expression vectors and host cells for the production of purified HJAK2 peptide, antibodies capable of binding to HJAK2, inhibitors which bind to HJAK2 and pharmaceutical compositions based on HJAK2 specific antibodies or inhibitors. The invention specifically provides for diagnostic assays based on altered hjak2 expression and which allow identification of such a condition. These assays utilize probes which comprise oligomers, fragments, or portions of hjak2 or its regulatory elements or antibodies specifically binding HJAK2.

Abstract: The synthesizer and method provide a relatively wideband swept frequency signal and include generating a first swept frequency signal with a first generator, and successively switching between different frequency signals with a second generator. Such switching creates undesired phase discontinuities in the output swept frequency signal. The first swept frequency signal is combined with the successively switched different frequency signals to produce the relatively wideband swept frequency signal, and the second generator is calibrated to reduce the undesired phase discontinuities during switching based upon the output swept frequency signal.

Abstract: The phase continuous synthesizer and method generate a relatively wideband swept frequency signal with the use of a first generator for generating a first swept frequency signal, and a second generator successively switching between different frequency signals while creating undesired phase discontinuities during switching. A mixer is connected to the first and second generators for mixing the first swept frequency signal and the successively switched different frequency signals to produce the relatively wideband swept frequency signal, and a phase coasting unit is connected downstream of the mixer to reduce the undesired phase discontinuities created during switching in the relatively wideband swept frequency signal.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (PANEC-1 and PANEC-2) from human pancreas cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode PANEC-1 and PANEC-2, expression vectors for the production of purified PANEC-1 and PANEC-2, antibodies capable of binding specifically to PANEC-1 and PANEC-2, hybridization probes or oligonucleotides for the detection of PANEC-1- or PANEC-2-encoding nucleotide sequences, genetically engineered host cells for the expression of PANEC-1 and PANEC-2, diagnostic tests for chemokine activation based on PANEC-1- and PANEC-2-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.

Abstract: A phased array antenna includes a transmission line network, e.g. optical or coaxial cable network, and a reference signal generator to provide a reference frequency signal to each of the antenna radiating elements. A phase calibrator generates a calibration signal. e.g. a swept frequency signal, on the transmission line network which is also reflected to create a reflected calibration signal. The phase calibrator determines a frequency difference between the calibration signal and the reflected calibration signal at each of a plurality of taps, and outputs a delay measurement signal to the antenna radiating elements, e.g. via an antenna controller, for adjusting a phase of the reference frequency signal.

Abstract: A digitally controlled frequency synthesizer has a first direct digital synthesizer that generates a first phase-coherent, time-varying frequency, and a second direct digital synthesizer that generates an offset frequency waveform. A plurality of cascaded frequency converters successively combine the offset frequency waveform with a reference frequency waveform to produce a plurality of waveforms having respectively different frequencies. A switch switches between the plurality of waveforms produced by the cascaded frequency converters to realize a second waveform. The operation of the second direct digital synthesizer is controlled so as to maintain phase continuity between respective ones of the plurality of waveforms contained in the second waveform as output by the switch. A mixer multiplies the first waveform by the second waveform to produce a time-varying output frequency.

Abstract: A chirp-based method and apparatus measures phase variation through a reference frequency transport cable for a phased array antenna. A chirp is injected into the a signal transport path from a remote transmit/receive portion of the antenna, so that the chirp is conveyed over the signal path, reflected from an upstream bandpass filter at a local transmit/receive portion of the antenna, and returned to a remote transmit portion of the antenna. Energy in the returned chirp is extracted by a downstream bandpass filter and correlated in a delay lock loop with energy in an auxiliary chirp signal, that is delayed relative to the injected chirp. The delay of the auxiliary chirp is adjusted to maximize the correlation output and provide an indication of the delay through the signal path.

Abstract: A chirp-based arrangement derives a measure of phase variation through a reference frequency transport cable of a phased array antenna architecture, such as a spaceborne synthetic aperture radar system. A direct digital synthesized chirp signal is injected in an upstream direction into the transport cable from a downstream end thereof, so that the chirp signal is transmitted in an upstream direction, reflected from an upstream bandpass filter, and returned in a downstream direction. At each of a plurality of nodes that are distributed along the transport cable, the two chirp signals are extracted and frequency domain-processed to derive said measure of transport delay through the cable between the source of the reference frequency signal and each of the nodes.

Abstract: 99 The invention provides human cyclic nucleotide phosphodiesterases (PDE8) and polynucleotides which identify and encode PDE8. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of PDE8.

Abstract: The present invention provides polynucleotides (mmlr-ccr or mphg-ccr) which encode novel chemokine receptors (MMLR-CCR OR MPHG-CCR). The present invention provides for screening methods for the detection of molecules that modulate receptor activity. The present invention also provides for antisense molecules, diagnostic molecules, genetically engineered expression vectors and host cells for the production of purified MMLR-CCR or MPHG-CCR; antibodies, agonists, antagonists and inhibitors of MMLR-CCR or MPHG-CCR; and pharmaceutical compositions and methods of treatment based on the polypeptide, its antibodies, antagonists and inhibitors. The invention further provides diagnostic and therapeutic compositions for the detection and treatment of infection, inflammation, proliferative disease, solid tumors and cardiovascular disease.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel purinergic PU2 receptor (PNR) expressed in human placenta. The present invention also provides for antisense molecules to the nucleotide sequences which encode PNR, expression vectors for the production of purified PNR, antibodies capable of binding specifically to PNR, hybridization probes or oligonucleotides for the detection of PNR-encoding nucleotide sequences, genetically engineered host cells for the expression of PNR, and diagnostic tests based on PNR-encoding nucleic acid molecules or antibodies produced against the polypeptide PNR.

Abstract: The present invention provides three zinc binding proteins (designated individually as ZB-1, ZB-2, and ZB-3, and collectively as ZB) and polynucleotides which identify and encode ZB. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding ZB and a method for producing ZB. The invention also provides for use of ZB and agonists, antibodies, or antagonists specifically binding ZB, in the prevention and treatment of diseases associated with expression of ZB. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding ZB for the treatment of diseases associated with the expression of ZB. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding ZB.

Abstract: The present invention provides two novel human cathepsin proteins (HCPs) and polynucleotides encoding HCPs. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HCPs. The invention also provides for the production and use of antibodies to HCPs in pharmaceutical compositions for the treatment of disease processes that include cancers, inflammation, metastasis and peptide and proenzyme processing. In addition, the invention provides for the production and use of inhibitors of HSPs in pharmaceutical compositions for the treatment of diseases. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding HCPs. The invention also provides for the use of antisense molecules in pharmaceutical compositions as therapeutics in cancers, inflammation, metastasis and peptide and proenzyme processing.